ClinicalTrials.Veeva

Menu

Multi-elemental Imaging of Lung Tissues With LIBS (Laser-induced Breakdown Spectroscopy) (MEDICO-LIBS)

Grenoble Alpes University Hospital Center (CHU) logo

Grenoble Alpes University Hospital Center (CHU)

Status

Completed

Conditions

Sarcoidosis
Idiopathic Pulmonary Fibrosis
Interstitial Lung Disease

Treatments

Diagnostic Test: Elemental analysis

Study type

Observational

Funder types

Other

Identifiers

NCT03901196
38RC18.134
2019-A00070-57 (Other Identifier)

Details and patient eligibility

About

Evaluate the feasibility of performing a multi-elemental imaging analysis of lung specimens from patients with ILDs, with an technology named LIBS (Laser Induced-Breakdown Spectroscopy)

Full description

There is a major health problem due to the environmental and occupational related exposures to mineral particles, metals, and dust. The impact on health is considerable in terms of prevalence, morbidity and healthcare costs. Pathologists rarely report the presence of a possible mineral or metal-related etiology in a specimen by lack of available and convenient technology. Therefore, several respiratory diseases are considered idiopathic.

Interstitial lung disease (ILD), also known as diffuse parenchymal lung disease (DPLD) is a group of lung diseases affecting the interstitium (the tissue and space around the air sacs of the lungs). In France, 15.000 new cases of ILD are diagnosed each year. ILD may be classified according to the cause. Idiopathic ILD are ILD of unknown causes. The most frequent idiopathic ILD are sarcoidosis and idiopathic pulmonary fibrosis (IPF).These two diseases are the core topic of the present study since they may relate to important mineral or metal exposure.

The overall goal of this MEDICO-LIBS study is to evaluate the feasibility of using a laser-induced breakdown spectroscopy (LIBS)-based instrument to image(ie, identify, localize and possibly quantify) metals within selected human specimens with ILDs.

Enrollment

86 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patient with ILD
  • Patient informed, and agreed to participate

Exclusion criteria

  • Patient opposed to participating in the study.
  • Patient without available specimen.
  • Patient under legal protection

Trial design

86 participants in 1 patient group

Interstitial Lung Disease
Description:
Ex : sarcoidosis, IPF
Treatment:
Diagnostic Test: Elemental analysis

Trial contacts and locations

4

Loading...

Central trial contact

Benoit Busser, PharmD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems